Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.~* A male or female who received the complete primary vaccination course according to his/her group allocation in the primary study~* Written informed consent obtained from the subject.~All subjects must satisfy the following criteria at entry into the challenge dose phase:~* A male or female who received the complete primary vaccination course according to his/her group allocation in the primary study.~* Subjects who participated in the long-term follow-up phase of the primary study and for whom the antibody concentrations were below specified value for anti-HAV antibodies and/ or for anti-HBs antibodies at the last available follow-up time-points.~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.~* Written informed consent obtained from the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the challenge dose phase of this study.~* If the subject is female, she must be of non-childbearing potential, i.e. either surgically sterilized; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after the vaccination.~Exclusion Criteria:~The following criteria should be checked at each follow-up visit. If any apply at study entry, the subject must not be included at that long-term follow-up visit.~* Use of any investigational or non-registered product (drug or vaccine) since the last blood sampling visit.~* Administration of a hepatitis A, hepatitis B or hepatitis combination vaccine since the primary vaccination course of the primary study.~* History of hepatitis A or hepatitis B infection.~* Administration of hepatitis A or hepatitis B immunoglobulins and/or any blood products within 3 months prior to blood sampling.~The following criteria should be checked before the challenge dose phase. If any apply, the subject must not be included in the challenge dose phase:~* Use of any investigational or non-registered product (drug or vaccine) within 30 days before the administration of the challenge dose or planned use during the study period outside the context of the study.~* Administration of a hepatitis A, hepatitis B or hepatitis combination vaccine between the primary vaccination course of the primary study and the challenge dose visit.~* History of hepatitis A or hepatitis B infection.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the challenge dose.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.~* Acute disease at the time of.~* Administration of immunoglobulins and/or any blood products within the three months preceding the administration of the challenge dose or planned administration before the final blood sampling point (one month after the challenge dose).~* Pregnant or lactating female.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- Twinrix Adult Group (Type: EXPERIMENTAL): Subjects received 2 doses of Twinrix™ Adult intramuscularly according to a 0, 6 month schedule in the primary study
- Twinrix Junior Group (Type: EXPERIMENTAL): Subjects received 3 doses of Twinrix™ Junior (= half dose Twinrix™ Adult) intramuscularly according to a 0, 1, 6 month schedule in the primary study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete